Table 2.
Primary and secondary outcomes according to treatment in the 502 randomised children according to allocation to new treatment (oral co-amoxiclav) or standard treatment (intravenous ceftriaxone followed by oral co-amoxiclav). Figures are means (SD) unless specified otherwise
| Parameter | New treatment (n=244) | Standard treatment (n=258) | Mean difference (95% CI) |
|---|---|---|---|
| Short term outcomes | |||
| Time to defervescence (hours) | 36.9 (19.7) (n=241) | 34.3 (20) (n=253) | 2.6 (−0.9 to 6) |
| White cell count (×109/l)* | 9.8 (3.5) (n=230) | 9.5 (3.1) (n=243) | 0.3 (−0.3 to 0.9) |
| Neutrophils (×109/l)* | 3.0 (2.2) (n=207) | 2.8 (1.9) (n=217) | 0.2 (−0.2 to 0.6) |
| Erythrocyte sedimentation rate (mm in first hour)* | 50.8 (32) (n=170) | 52.6 (27.9) (n=168) | −1.8 (−8.2 to 4.7) |
| C reactive protein (mg/l)*† | 9.3 (20.9) (n=235) | 8.2 (15.4) (n=251) | 1.1 (−2.6 to 4.1) |
| Sterile urine | 185/186 (99.45%) | 203/204 (99.5%) | −0.05% (−1.5% to 1.4%) |
| Primary outcome | |||
| Scar on renal scan at 12 months | 27/197 (13.7%) | 36/203 (17.7%) | −4% (−11.1% to 3.1%) |
*Parameters obtained 72 hours after start of antibiotic treatment.
†Ratio between obtained value and upper limit of normal reference values for each laboratory.